
## Francesco Barletta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10182422/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging–targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy. European Urology, 2020, 77, 733-741.	0.9	85
2	Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. European Urology Oncology, 2021, 4, 697-713.	2.6	84
3	Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial. European Urology, 2020, 77, 576-580.	0.9	55
4	The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy. European Urology, 2018, 74, 4-7.	0.9	50
5	Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. European Urology Oncology, 2022, 5, 1-17.	2.6	50
6	Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing Radical Prostatectomy for Localised Prostate Cancer. European Urology Oncology, 2021, 4, 42-48.	2.6	40
7	Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging–targeted Biopsy. European Urology Oncology, 2020, 3, 739-747.	2.6	31
8	A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 10.e1-10.e6.	0.8	20
9	Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. European Urology, 2019, 75, 817-825.	0.9	17
10	Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review. European Urology Oncology, 2022, 5, 153-163.	2.6	15
11	Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions. BJU International, 2022, 129, 201-207.	1.3	11
12	How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 103.e17-103.e24.	0.8	8
13	Initial Experience with Radical Prostatectomy Following Holmium Laser Enucleation of the Prostate. European Urology Focus, 2020, 7, 1247-1253.	1.6	7
14	Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era?. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 784.e1-784.e9.	0.8	7
15	Reducing the Risk of Postoperative Complications After Robot-assisted Radical Prostatectomy in Prostate Cancer Patients: Results of an Audit and Feedback Intervention Following the Implementation of Prospective Data Collection. European Urology Focus, 2022, 8, 431-437.	1.6	5
16	Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series. Prostate, 2022, 82, 1170-1175.	1.2	5
17	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol. BMJ Open, 2021, 11, e040531.	0.8	4
18	Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. European Urology Oncology, 2022, 5, 285-295.	2.6	4

#	Article	IF	CITATIONS
19	Diagnostic and prognostic factors in patients with prostate cancer: a systematic review. BMJ Open, 2022, 12, e058267.	0.8	4
20	Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series. Prostate Cancer and Prostatic Diseases, 2021, 24, 1137-1142.	2.0	3
21	Has the COVID-19 outbreak changed the way we are treating prostate cancer? An EAU – YAU Prostate Cancer Working Group multi-institutional study. Central European Journal of Urology, 2021, 74, 362-365.	0.2	3
22	Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy. Journal of Urology, 2022, 208, 1046-1055.	0.2	1